Is Eyepoint Pharmaceuticals Inc (EYPT) overvalued? · rev $1.2M
Eyepoint Pharmaceuticals Inc (EYPT) is a biotechnology company listed on NASDAQ.
This page asks whether Eyepoint Pharmaceuticals Inc (EYPT) looks expensive on cached numbers — not a short thesis.
Latest reported EYPT revenue for 2026-06-30 was $1.2M. Net income was -$179.3M. Revenue was up 72.8% from 2026-03-31 to 2026-06-30. EYPT currently screens at market cap $1.10B.
EYPT currently screens at market cap $1.10B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next EYPT 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the EYPT stock page for the full model, not this heading.
Not investment advice.